D.E. Shaw & Co
OVID icon

D.E. Shaw & Co’s Ovid Therapeutics OVID Stock Holding History

D.E. Shaw & Co’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$99.2K Buy
+36,877
New +$95.2K ﹤0.01% 4643
2024
Q2 		– Sell
-71,264
Closed -$217K – 4763
2024
Q1 		$217K Sell
71,264
-7,003
-9% -$23.4K ﹤0.01% 3893
2023
Q4 		$252K Sell
78,267
-6,041
-7% -$20.6K ﹤0.01% 3806
2023
Q3 		$324K Sell
84,308
-22,974
-21% -$82.6K ﹤0.01% 3590
2023
Q2 		$352K Sell
107,282
-231,878
-68% -$787K ﹤0.01% 3549
2023
Q1 		$875K Sell
339,160
-167,167
-33% -$396K ﹤0.01% 3247
2022
Q4 		$942K Sell
506,327
-184,996
-27% -$315K ﹤0.01% 3487
2022
Q3 		$1.27M Sell
691,323
-198,041
-22% -$414K ﹤0.01% 3407
2022
Q2 		$1.91M Buy
889,364
+663
+0.1% +$1.6K ﹤0.01% 3114
2022
Q1 		$2.79M Buy
888,701
+129,605
+17% +$408K ﹤0.01% 2978
2021
Q4 		$2.44M Buy
759,096
+30,166
+4% +$103K ﹤0.01% 3180
2021
Q3 		$2.45M Sell
728,930
-16,985
-2% -$61.9K ﹤0.01% 2844
2021
Q2 		$2.92M Buy
745,915
+160,210
+27% +$632K ﹤0.01% 2557
2021
Q1 		$2.35M Buy
585,705
+373,312
+176% +$1.24M ﹤0.01% 2458
2020
Q4 		$490K Buy
+212,393
New +$990K ﹤0.01% 3400

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

D.E. Shaw & Co's OVID Position: Q2 2026 in Review

D.E. Shaw & Co opened a new position in Ovid Therapeutics (OVID) in Q2 2026: 36,877 shares worth $99.2K. The stake represents ﹤0.01% of the portfolio and ranks #4643 among its holdings. This is a return to the name: D.E. Shaw & Co previously reported a position in OVID as recently as Q1 2024.

D.E. Shaw & Co first reported a position in OVID in Q4 2020 and has held it in 15 quarters since. The position peaked at $2.92M in Q2 2021. 131 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • D.E. Shaw & Co held 36,877 shares of Ovid Therapeutics worth $99.2K as of Q2 2026.
  • Ovid Therapeutics was a new D.E. Shaw & Co position in Q2 2026.
  • Ovid Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #4643 holding.
  • D.E. Shaw & Co first reported a position in Ovid Therapeutics in Q4 2020 and has held it in 15 quarters since.
  • D.E. Shaw & Co's Ovid Therapeutics position peaked at $2.92M in Q2 2021.
  • 131 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.